AMG 386 (Trebananib) in Ovarian Cancer (TRINOVA-2)
Status:
Terminated
Trial end date:
2017-04-19
Target enrollment:
Participant gender:
Summary
To determine if AMG 386 plus pegylated liposomal doxorubicin (PLD) is superior to placebo
plus PLD as measured by progression-free survival (PFS)
The hypothesis for this study is that AMG 386 plus PLD will prolong PFS compared to placebo
plus PLD in women with recurrent partially platinum sensitive or resistant epithelial
ovarian, primary peritoneal or fallopian tube cancer.